Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan Women

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  McKinnon, Lyle R ^a,b   Kimani, Makobu ^b   Wachihi, Charles ^b   Nagelkerke, Nico J ^c   Muriuki, Festus K ^b   Kariri, Anthony ^b   Lester, Richard T ^b,d,g   Gelmon, Lawrence ^b,d   Ball, T Blake ^d,e   Plummer, Francis A ^b,d,f   Kaul, Rupert ^a,b   Kimani, Joshua ^b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d UNIVERSITY OF MANITOBA   (Canada)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^g BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; TRIOMIN; UNCLASSIFIED DRUG;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; KENYA; LIFE EXPECTANCY; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; PROSTITUTION; TREATMENT OUTCOME; VIRUS LOAD; DRUG EFFECT; IMMUNOLOGY; LONGITUDINAL STUDY; MULTIVARIATE ANALYSIS; STATISTICAL MODEL;

ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; KENYA; LINEAR MODELS; LONGITUDINAL STUDIES; MULTIVARIATE ANALYSIS;

EID: 77955393670     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011434     Document Type: Article

References (19)

1. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, et al. (2008) Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300: 51-59.
2. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, et al. (1999) AIDSrelated opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 282: 2220-2226.
3. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, et al. (2000) Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30 Suppl 1: S5-14.
4. Miro JM, Lopez JC, Podzamczer D, Pena JM, Alberdi JC, et al. (2006) Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis 43: 79-89.
5. Gazzola L, Tincati C, Bellistri GM, Monforte A, Marchetti G (2009) The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 48: 328-337.
6. Siddique MA, Hartman KE, Dragileva E, Dondero M, Gebretsadik T, et al. (2006) Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. J Infect Dis 194: 661-665.
7. Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, et al. (2003) Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 33: 125-133.
8. Micheloud D, Berenguer J, Bellon JM, Miralles P, Cosin J, et al. (2008) Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency. J Infect 56: 130-136.
9. Benito JM, Lopez M, Lozano S, Ballesteros C, Martinez P, et al. (2005) Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 38: 373-381.
10. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, et al. (2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virusinfected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187: 1534-1543.
11. Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, et al. (2005) Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 191: 1670-1679.
12. Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, et al. (2006) Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 194: 29-37.
13. Wei J, Lederman MM, Hunt P, Sieg SF, Haley K, et al. (2009) Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. 199: 1177-1185.
14. Delobel P, Nugeyre MT, Cazabat M, Sandres-Saune K, Pasquier C, et al. (2006) Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J Virol 80: 10229-10236.
15. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, et al. (2009) Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 48: 350-361.
16. Okulicz JF, Grandits GA, Weintrob AC, Landrum ML, Ganesan A, et al. (2010) CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis 50: 1187-1191.
17. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
18. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352-1363.
19. Dieffenbach CW, Fauci AS (2009) Universal voluntary testing and treatment for prevention of HIV transmission. Jama 301: 2380-2382.